On 14 June, Evgeny Shlyakhto, Director General of Almazov Centre, signed a number of memoranda of understanding (MoU) at the St. Petersburg International Economic Forum.
A MoU was signed with the Moscow Institute of Physics and Technology (MIPT) for long-term cooperation in research, education and technology transfer in biotechnology, genetics and bioinformatics.
Another Memorandum of Understanding was signed with Pharmsintez PJSC on joint work to create a domestic innovative drug for personalized diagnosis and treatment of malignant brain tumors. According to the preliminary agreements, Pharmsintez PJSC will act as an industrial partner of Almazov Centre, which will complete the full cycle of active pharmaceutical ingredient (API) development and produce the required amount of the drug for the first phase of clinical trials.